Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
HIV
Interventions
DRUG

Efavirenz

The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).

Trial Locations (2)

46202

Indiana Clinical Research Center (ICRC), Indianapolis

Indiana University, Indianapolis

All Listed Sponsors
lead

Indiana University

OTHER

NCT00668395 - Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics | Biotech Hunter | Biotech Hunter